Here is a story that ran in The Seattle Times a few days ago. http://tinyurl.com/3dwvgbSeeking a fresh infusion of cash and global marketing expertise, ZymoGenetics cut a licensing deal with European pharmaceutical giant Bayer HealthCare to jointly deploy the Seattle biotechnology company's first expected product since it went public five years ago. ZymoGenetics said the agreement it is announcing today will bring $30 million upfront from Bayer and $40 million after the federal approval of rThrombin, which helps control surgical bleeding.My only concern (if you read the entire article) is the part about Bayer getting the right to market rThrombin outside the U.S. indefinitely while only paying ZymoGenetics "up to 20 percent in royalties." I understand the reality involved, ZymoGenetics is just too small to take on a task that huge, but the greedy side of me is asking "you couldn't do better than 20%???" 60/40 I'd be fine with, but 80/20? We'll see how it turns out. MESuther13
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. M